Clinical trial · Interventional
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting
NCT00174434CI-TRIAL-00001939completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paclitaxel | Drug | Paclitaxel | ALIAS |
| SU011248 | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: SU011248
- Drug: Paclitaxel
Primary outcomes (1)
- measure
- Safety of the combination of SU011248 and paclitaxel
- timeFrame
- 9/05-7/07
Secondary outcomes (3)
- measure
- Pharmacokinetics of each medication
- timeFrame
- 9/05-7/07
- measure
- Objective disease response
- timeFrame
- 9/05-7/07
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer with evidence of unresectable, locally recurrent or metastatic disease. * Candidate for treatment with paclitaxel. Exclusion Criteria: * Prior chemotherapy in the advanced disease setting. * HER2 positive disease unless previously treated with trastuzumab.
References
Publications (0)
Data not yet available
No reference posted for this study.